IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Bradda Head  Lithium exceeds targets, secures US$3 million royalty and moves closer to production
Bradda Head Lithium exceeds targets, secures US$3 million royalty and moves closer to productionView Video
IntelliAM aiming for significant growth with £5 million Aquis IPO
IntelliAM aiming for significant growth with £5 million Aquis IPOView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 91.00
Bid: 93.35
Ask: 93.36
Change: 0.01 (0.011%)
Spread: 0.01 (0.011%)
Open: 90.48
High: 91.08
Low: 90.08
Prev. Close: 90.23
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European bourses hold on to U.S. CPI boost

Wed, 10th Aug 2022 17:02

Aug 10 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com

EUROPEAN BOURSES HOLD ON TO U.S. CPI BOOST (1150 EDT/1550 GMT)

It may not be the game changer some investors were hoping for, but the weaker than expected U.S. inflation data triggered a substantial bounce on Wall Street which swiftly made its way to equity markets on the other side of the Atlantic.

The pan-European STOXX 600 which was broadly flat all morning, jumped 0.8% after the CPI reading suggested that peak inflation might just be in sight.

European stocks held on to these gains in afternoon trading and ended the session with a 0.9% gain, a moderate rise which suggests there's still some angst remaining on the monetary policy front.

“While a peak in inflation is welcome news, it’s probably not enough to allow the Fed to ease off its tightening or to put recession fears to bed", Mike Bell, a strategist at J.P. Morgan Asset Management, wrote commenting the U.S. indicator.

Most regional bourses and sectors ended higher, but pharmaceuticals underperformed with their index losing 0.8%.

Among its constituents, German biotech Evotec lost over 8% after Morgan Stanley downgraded the stock.

Swiss eye care device maker Alcon slid 6.4% on a 2022 guidance cut, while heavyweights Sanofi and GSK also saw their shares lose 7.8% and 5.4% respectively.

(Julien Ponthus)

RETAIL TRADERS SEE U.S. RECESSION THIS YEAR - CHARLES SCHWAB (1120 EDT/ 1520 GMT)

Nearly three in four retail traders anticipate a recession in the United States will begin this year as the Federal Reserve moves to wean the economy off pandemic-era stimulus measures, according to a survey by Charles Schwab.

However, 69% of those traders expect the recession to only last a year or less, according to the quarterly report, which examines patterns of active users of online brokerages Charles Schwab and TD Ameritrade.

"Many traders are not taking specific action to hedge against a recession," Schwab's head of trading and education Barry Metzger said.

The Fed has been trying to cool prices without tipping the economy over into recession. With U.S. GDP having contracted for two straight quarters, the world's largest economy now fits an often-cited definition of a recession.

However, the National Bureau of Economic Research, which also factors in other economic indicators such as wages and employment, has not declared a recession yet.

Data released on Wednesday showed U.S. consumer prices decelerated in July as gasoline prices dropped sharply.

"There’s still plenty to trouble central bankers... and few will conclude today’s fall quashes the need for further aggressive rate hikes," said Danni Hewson, analyst at investment platform AJ Bell.

(Niket Nishant)

COOL YOUR JETS: CPI, MORTGAGE DEMAND (1050 EDT/1450 GMT)

Data released on Wednesday served up a refreshing gazpacho of cooling inflation and resiliency in the housing market.

The Labor Department's much anticipated consumer price index (CPI) report was the star of the show, and it offered the refreshing news that consumer price growth cooled more than expected in July.

CPI, which measures the prices urban consumers pay for a basket of goods, was unchanged from June and up 8.5% year-over-year, marking a 0.6 percentage point deceleration, thanks in large part to softening commodity prices.

Stripping out volatile food and energy items, so-called "core" CPI rose by 0.3% on a monthly basis - a 0.4 percentage point deceleration - and grew 5.9% from a year ago, repeating last month's print.

Line by line, gasoline prices and airfares tumbled by 7.7% and 7.8% respectively, mitigating price increases in food, housing, drugs, and new cars.

"We’re seeing some a relief in transitory inflation," says Peter Cardillo, chief market economist at Spartan Capital Securities in New York. "Gas prices are coming down, food prices are beginning to stabilize, so that’s good news for the consumer."

"Does this raise the possibility of the Fed changing its tune? I suspect not," Cardillo adds. "We should still see a 50 to 75 basis point (interest) rate hike in September."

But the odds of Powell & Co implementing a third consecutive 75 basis point interest rate hike plunged in the wake of the report. The market now sees a 32% chance of that occurring, down from 68% before the release, according to Fedwatch.

While we're not out of the inflation woods, the notion that peak inflation is in the rear view mirror is gathering steam.

"With the economy much cooler than in 2021, inventory levels higher, and gas prices down in the first ten days of August, inflation is probably past the peak," says Bill Adams, chief economist at Comerica Bank.

A quick glance and year-over-year core CPI along with other major indicators reveals the long downhill trek inflation must follow to approach the Fed's average annual 2% target. Even so, down is down even if the slope is frustratingly gradual:

Now would be an opportune time to drop in on our cranky pal the misery index, which adds headline CPI to the unemployment rate.

The jobless rate, typically the cause of most of the misery index's pain, is now at pre-pandemic lows. Soaring prices have been the leading cause of consumer misery since the second half of 2021 and the July CPI cooldown brings the MI to its lowest level since April:

In today's also-ran data, demand for home loans held steady last week even as mortgage rates crept modestly higher.

The average 30-year fixed contract rate inched ever so slightly higher, adding 3 basis points to 5.47%.

While applications for loans to purchase homes inched 1.4% lower, refi demand more than made up for it, rising 3.5% for a total nominal demand increase of 0.2%.

Still, the overall trend shows softening homebuyer demand as rising home prices and the upward march of mortgage rates have caused affordability to evaporate.

"The purchase market continues to experience a slowdown, despite the strong job market," writes Joel Kan, associate vice president of economic and industry forecasting at MBA. "Activity has now fallen in five of the last six weeks, as buyers remain on the sidelines due to still-challenging affordability conditions and doubts about the strength of the economy."

Nancy Vanden Houten, lead U.S. economist at Oxford Economics, sees a bumpy road ahead.

"We expect that mortgage rates will continue to be volatile in the weeks ahead, tracking the volatility in the Treasury market," Houten writes.

The graphic below shows overall mortgage activity has plummeted by 62.9% compared with the same week last year:

Wall Street ate up the data, jumping sharply higher.

All three major U.S. stock indexes are bright green, powered by the usual interest-rate sensitive market movers Microsoft , Apple and Amazon.com.

Energy stocks are an island of red in a sea of green, pulled lower by tumbling crude prices.

(Stephen Culp)

U.S. STOCKS POP ON CPI SURPRISE (0955 EDT/1355 GMT)

The main U.S. indexes are sharply higher in early trade on Wednesday as they celebrate a slower-than-expected rise in inflation last month which has prompted traders to cut their bets on a third straight 75-basis-point interest rate hike in September.

U.S. July CPI headline and core readings came in below estimates.

Ten of 11 major S&P 500 sectors are higher with materials among the strongest groups. Banks are also among early outperformers. That said, growth is outperforming value.

Meanwhile, amid the rally, the CBOE Volatility index is falling to flirt with the 20.00 level, while hitting its lowest level since April 21. The dollar and the U.S. 10-year Treasury yield are under pressure.

Gennadiy Goldberg, interest rate strategist, at TD Securities, said, “I think (the market reaction) just shows you the whipsaw on market price action every time you get a piece of data that can move the expectations for Fed rate hikes. The downside miss is certainly not something the markets were positioned for, I think the market was really one way positioned for a higher inflation print and higher Fed pricing.”

Goldberg added, “There’s still quite a bit of data between now and September… we’ve only gotten one out of two CPI prints before then and we’ve got another payroll print as well and a full set of data effectively for August, so I think the jury’s still very much out on September.”

Here is an early trade snapshot:

(Terence Gabriel, Karen Brettell)

U.S. STOCK FUTURES HEAT UP AS CPI COOLS (0900 EDT/1300 GMT)

U.S. equity index futures are surging in the wake of the release of the latest data on inflation.

July CPI month-over-month and year-over-year came in below expectations. Core readings were also cooler than estimates:

With the data dousing expectations of an aggressive rate hike by the Federal Reserve next month, CME Nasdaq 100 futures are leading U.S. equity index futures' gains, advancing more than 2% from around 0.5% before the data.

European stocks, which were flat for most of the session, jumped in the immediate aftermath of the U.S. inflation figures with the pan-European STOXX 600 rising around 1% from 0.1% ahead of the data.

All 11 S&P 500 sector SPDR ETFs are higher in premarket trade with consumer discretionary, tech and communication services posting the biggest gains.

Gold and bitcoin are jumping, while the dollar, and the U.S. 10-Year Treasury yield are sliding.

Regarding the inflation data, Chris Beauchamp, Chief Market Analyst at IG Group, the trading platform, said:

"The softer inflation print has given risk assets the new lease on life they were looking for, and seems to confirm the idea that some sort of Fed pause might take place in the final months of 2022."

Beauchamp added "Futures are surging and the dollar is firmly on the back foot. It looks like the drop in commodity prices has done its job, and while inflation is still at levels that would be considered eye-watering a year ago, the turn in direction has been greeted with relief by risk assets. Having struggled for a few days, equities seem well-placed to push on from here, extending their summer rally."

Here is a premarket snapshot:

FOR WEDNESDAY'S LIVE MARKETS' POSTS PRIOR TO 0900 EDT/1300 GMT - CLICK HERE:

(Terence Gabriel is a Reuters market analyst. The views expressed are his own)

More News
1 Jul 2024 23:37

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge

July 1 (Reuters) - A Delaware judge rebuffed a request by GSK and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward.

Read more
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

Read more
20 Jun 2024 16:01

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.

Read more
11 Jun 2024 00:32

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

June 10 (Reuters) -

Read more
10 Jun 2024 22:49

Latest trial over Zantac cancer claims called off as plaintiff drops case

June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced.

Read more
7 Jun 2024 19:34

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
27 May 2024 06:00

US, European nations consider vaccinating workers exposed to bird flu

CHICAGO/LONDON, May 27 (Reuters) - The United States and Europe are taking steps to acquire or manufacture H5N1 bird flu vaccines that could be used to protect at-risk poultry and dairy workers, veterinarians and lab technicians, government officials said, moves influenza experts say could curb the threat of a pandemic.

Read more
23 May 2024 19:21

Zantac not a cause of woman’s cancer, jury says in first trial over drug

CHICAGO, May 23 (Reuters) - A jury in Chicago on Thursday rejected an Illinois woman’s claim that the now discontinued heartburn drug Zantac caused her colon cancer, in the first trial out of thousands of lawsuits making similar allegations.

Read more
22 May 2024 22:59

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 22 (Reuters) -

Read more
10 May 2024 17:21

STOXX 600 closes at record high on earnings, rate cut optimism

Rio Tinto considered bid for BHP-target Anglo American -report

*

Read more
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.